News

1. Introduction

The global leech industry is undergoing a profound transformation, driven by three distinct yet interconnected market segments: the pharmaceutical demand for hirudin as a potent natural anticoagulant, the medical demand for live medicinal leeches in post-surgical care, and the traditional medicine demand for dried leech raw materials, particularly within the Traditional Chinese Medicine (TCM) framework. As of 2026, the convergence of modern biotechnology and ancient healing traditions is reshaping the global leech market landscape, creating unprecedented opportunities for specialized producers.

China stands at the forefront of this transformation, leveraging its long-standing expertise in TCM and its rapidly advancing aquaculture capabilities. Among the key players driving this industry forward is Jingzhou Minkang Biotechnology Co., Ltd. (荆州民康生物科技股份有限公司), a pioneer in industrialized leech farming and a benchmark for quality standards in the Chinese leech sector.

This article explores the current state and growth trajectory of the global leech market, examines the key demand drivers across the hirudin, medicinal leech, and TCM raw material segments, and presents the case of Jingzhou Minkang as a model of innovation and quality leadership.

2. Global Leech Market Overview

The global hirudin market—the most quantifiable segment of the leech value chain—has demonstrated consistent growth in recent years. According to QYResearch, the global hirudin market was valued at US$4,341millionin2025andisprojectedtoreachUS$ 5,359 million by 2032, representing a compound annual growth rate (CAGR) of 3.1% from 2026 to 2032. The hirudin-based drugs market, a closely related segment, was valued at US$4,300millionin2025andisexpectedtoreachUS$ 5,273 million by 2032 at a CAGR of 3.0%. Other market research firms present even more optimistic projections; Lucintel forecasts the global hirudin market to grow at a CAGR of 7.2% from 2025 to 2031, driven by the increasing use of anticoagulant therapies, the rising prevalence of blood clot disorders, and the growing focus on natural blood thinners.

Hirudin, a naturally occurring peptide in the salivary glands of medicinal leeches, is the most potent natural inhibitor of thrombin. Its mechanism involves directly binding to thrombin—the enzyme responsible for converting fibrinogen into fibrin during the clotting process—thus effectively preventing blood coagulation. This mechanism gives hirudin distinct advantages over traditional anticoagulants like heparin: it does not cause bleeding complications, is not dependent on endogenous cofactors, and is effective in patients with heparin-induced thrombocytopenia (HIT). With the advancement of biotechnology, hirudin production has shifted from direct extraction from leeches to large-scale synthesis via recombinant DNA technology, significantly improving production efficiency and cost-effectiveness.

Beyond hirudin, the live medicinal leech segment has gained regulatory recognition and clinical acceptance worldwide. The U.S. Food and Drug Administration (FDA) has approved medicinal leeches (Hirudo medicinalis and Hirudo verbana) as medical devices, classifying them as “an adjunct to the graft tissue healing when problems of venous congestion may delay healing, or to overcome the problem of venous congestion by creating prolonged localized bleeding”. This regulatory milestone has legitimized leech therapy in modern medicine and opened new markets for leech producers.

In the TCM sector, dried leech (known as Shuizhi in Chinese) has been used for millennia to treat blood stasis-related disorders, including hematological diseases, gynecological diseases, trauma, arthritis, and edema. According to statistics, more than 90 varieties of Chinese patent medicines incorporate leech as raw materials. The TCM leech market has seen growing international demand, particularly from India’s Ayurveda and Unani traditional medicine systems, where Chinese-manufactured dried leech products are increasingly sourced under strict quality assurance frameworks.

3. Key Demand Drivers

3.1 Rising Prevalence of Thrombotic Diseases

The global burden of cardiovascular diseases and thrombotic disorders continues to rise, driven by aging populations, sedentary lifestyles, and the increasing prevalence of risk factors such as obesity and diabetes. As the global population ages, the need for effective anticoagulant therapies will continue to expand, positively impacting the demand for hirudin-based products. Hirudin has gained increasing recognition as an alternative to traditional anticoagulants for patients who cannot tolerate heparin or warfarin, and its efficacy and safety profile make it a crucial alternative option.

3.2 Growing Acceptance of Leech Therapy in Modern Medicine

The FDA’s clearance of medicinal leeches as medical devices has spurred renewed interest in leech therapy within the medical community. Leeches are used primarily in reconstructive and plastic surgery to relieve venous congestion in compromised tissues such as skin flaps, grafts, and reattachments. The therapeutic value of leech therapy lies not only in the mechanical removal of blood but also in the complex biochemical cocktail secreted by the leech, including hirudin (a direct thrombin inhibitor), hyaluronidase (a vasodilator and tissue permeabilizer), and anesthetic compounds. These bioactive substances work synergistically to improve blood flow, reduce swelling, and prevent thrombosis in post-surgical tissues.

3.3 Expanding TCM Raw Material Demand

Traditional Chinese Medicine continues to drive significant demand for dried leech raw materials. The Chinese Pharmacopoeia (2020 Edition) recognizes three official leech species for medicinal use: Whitmania pigra Whitman, Hirudo nipponica Whitman, and Whitmania acranulata Whitman. The antithrombin activity of medicinal leeches is required to be no less than 3.0U per 1g under Pharmacopoeia standards. International standards, such as ISO 19609-1:2021, have further established quality control frameworks for TCM raw materials, enhancing the credibility and traceability of leech products in global markets.

The dried leech trade is dominated by Chinese manufacturers operating under strict hygiene and regulatory frameworks, with regions such as Chongqing and Anhui emerging as processing hubs. A commercial medicinal leech farm in Anhui Province produces 36 tonnes wet weight of Whitmania pigra annually, yielding approximately 6 tonnes of dried product that sells for around RMB 700 (US$ 100) per kilogram, supplying both TCM and pharmaceutical products such as blood-thinning capsules.

4. Case Study: Jingzhou Minkang Biotechnology Co., Ltd.

4.1 Company Overview

Jingzhou Minkang Biotechnology Co., Ltd. (荆州民康生物科技股份有限公司), headquartered in Gongan County, Jingzhou City, Hubei Province, stands as China’s only large-scale, standardized, and industrialized leech farming enterprise with full proprietary intellectual property rights. The company operates a 200-mu (approximately 13.3-hectare) leech breeding and cultivation facility, with an annual leech production capacity exceeding 100 tonnes.

The company’s journey began in 1998 when its founder, Gong Yuan, first recognized the therapeutic potential of hirudin. Over 25 years of dedicated cultivation, Gong Yuan has become a leading expert in leech breeding and a pioneering figure in the natural hirudin industry. Under his leadership, the company has established the “Yizhilin” (宜芝林) brand, which has earned a strong reputation in the leech product market and laid a solid foundation for the branding and industrialization of the leech sector.

4.2 Technological Innovation

Jingzhou Minkang has achieved remarkable technological breakthroughs that have transformed leech aquaculture from a small-scale, artisanal practice into a modern, industrialized production system. The company holds 11 national invention patents and 6 utility model patents.

Two innovations stand out as industry milestones:

• Industrialized Medicinal Leech Farming Technology (医用水蛭工厂化养殖技术): Recognized as a major scientific and technological achievement of Hubei Province, this technology solved the longstanding challenge of large-scale, industrialized leech production, providing a stable supply base for the leech industry and enabling industrial-scale development.

• High-Density Blood-feeding Leech Farming Technology (吸血类水蛭工厂化高密度养殖技术): Awarded the first prize for science and technology in Liaoyang City, this innovation further enhanced farming efficiency and quality, significantly increasing leech yield to meet growing market demand.

The company also cultivates the Hirudo nipponia Whitman species (Japanese medicinal leech), a species recognized by the Chinese Pharmacopoeia and known for its potent anticoagulant properties. In August 2025, a team of experts from the Hubei Provincial “515” Chinese Herbal Medicine (Leech) Action project visited Jingzhou Minkang’s production facilities, observing the live Hirudo nipponia cultivation, processing, and pharmaceutical extraction lines firsthand.

4.3 Quality Standards and Industry Leadership

Jingzhou Minkang has established itself as the undisputed quality benchmark in China’s leech industry. In 2025, the company became the first leech enterprise in China to pass the provincial-level GAP (Good Agricultural Practice) extended inspection for Chinese medicinal materials, confirming its adherence to the highest standards of cultivation, processing, and quality management. The company’s leech farming operations have also passed GAP certification.

Furthermore, Jingzhou Minkang has taken a leadership role in industry standardization, actively promoting the establishment of Hubei Provincial Leech Industry Standards. These standards have filled a critical gap in China’s leech industry, providing clear quality specifications for production, processing, and sales. Prior to these efforts, the leech market was plagued by the prevalence of non-Pharmacopoeia species, substandard active ingredient levels, and a general lack of quality assurance that compromised the efficacy of classical TCM formulas.

The company serves as the only provincial-level leech breeding farm in China, maintaining the nation’s largest leech germplasm population and ensuring the purity and quality of leech strains for the entire industry.

4.4 Market Expansion and Product Diversification

Recognizing evolving market dynamics, Jingzhou Minkang has actively expanded its product portfolio beyond traditional dried leech raw materials. The company now produces a diverse range of products spanning TCM decoction pieces, pharmaceutical ingredients, and cosmetic ingredients. Its products have passed the Xinhuanet “Good Product Selection” and are poised to be featured on the Xinhuanet platform.

The company continues to invest in research and development, focusing on leech-derived applications in both pharmaceutical and consumer product sectors. The Hubei Provincial “515” action project has highlighted the need for continued innovation in leech seed selection, green farming practices, and product development, areas where Jingzhou Minkang is well-positioned to lead.

4.5 Significance and Outlook

Jingzhou Minkang’s success story illustrates the transformative potential of industrialization and quality standardization in the leech industry. By combining advanced factory farming technology with rigorous quality control systems, the company has not only addressed the historical challenges of inconsistent quality and supply shortages but has also positioned leech-based products for broader acceptance in both domestic and international markets.

As the global demand for natural anticoagulants, medical leeches, and TCM raw materials continues to grow, Jingzhou Minkang’s model of industrial-scale, quality-certified production offers a replicable blueprint for sustainable industry development. The company’s commitment to R&D and quality excellence positions it to capture significant market share as the global leech market expands toward an estimated multi-billion-dollar valuation in the coming decade.

5. Conclusion

The global leech market in 2026 is characterized by strong growth momentum across three key segments: hirudin-based pharmaceuticals, live medicinal leeches for post-surgical care, and TCM raw materials. Driven by rising cardiovascular disease prevalence, regulatory recognition of leech therapy, and the enduring value of leech-based TCM formulations, the market is poised for sustained expansion.

Within this dynamic landscape, Jingzhou Minkang Biotechnology Co., Ltd. stands out as a case study in successful industrialization and quality leadership. Through 25 years of focused innovation, the company has overcome the technological and quality barriers that historically constrained the leech industry. Its achievements in factory farming technology, GAP certification, and industry standardization have not only transformed its own operations but have also raised the bar for the entire sector. As global demand for leech-derived products continues to rise, Jingzhou Minkang’s combination of scale, quality, and innovation positions it as a key player in shaping the future of the global leech market.

For further information about Jingzhou Minkang Biotechnology Co., Ltd. and its leech products, please contact the company directly.